Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies, Inc. (SIGA) is a commercial-stage pharmaceutical company whose news flow centers on its role in health security and orthopoxvirus antivirals. The company regularly issues press releases on its financial results, government contracts, regulatory milestones, and corporate developments, giving investors and observers insight into the performance and direction of the business.
A recurring theme in SIGA’s news is the commercial progress of its flagship antiviral medicine, TPOXX (tecovirimat). Company updates describe product revenues from oral and IV TPOXX, including deliveries to the U.S. Strategic National Stockpile and sales to the U.S. Department of Defense and international customers. Releases also discuss procurement orders, outstanding orders, and the mix of domestic and international product sales.
Regulatory and development milestones are another key news category. SIGA has reported authorizations and approvals of TPOXX in multiple jurisdictions, including approval in Japan under the name TEPOXX for orthopoxvirus-related indications. The company also announces modifications to its BARDA 19C contract that add funding for pediatric development and manufacturing activities, reflecting ongoing development work around TPOXX.
Quarterly and annual earnings releases provide detailed financial statements, highlighting product sales, total revenues, operating income or loss, and net income or loss. These updates often include commentary from management on business performance, health security priorities, and the status of government and international contracts.
In addition, SIGA’s news includes governance and capital allocation items, such as the declaration of special cash dividends and appointments to the board of directors. Together, these disclosures offer a view into SIGA’s financial results, strategic relationships with governments and public health agencies, and its continuing focus on TPOXX as a countermeasure against orthopoxvirus-related diseases.
SIGA Technologies has announced a collaboration with Bioarchitech to investigate the use of TPOXX® (tecovirimat) combined with Bioarchitech's oncolytic vaccinia immunotherapy platform. This partnership aims to enhance the efficacy of cancer treatments by utilizing TPOXX to allow for higher doses of vaccinia vectors, potentially improving patient outcomes. TPOXX has FDA approval for smallpox treatment and has shown effectiveness against various orthopoxviruses. This collaboration reflects SIGA's commitment to advancing health security through innovative therapies.
SIGA Technologies (SIGA) announced its participation in the Edison Group’s Global Healthcare Open House Conference on January 25-27, 2022. CEO Phil Gomez will present and be available for 1x1 meetings. The company presentation will be available on demand starting January 26 at 7am ET on edison.com. This follows SIGA's recent FDA and EMA approvals for its lead product, TPOXX, an antiviral for smallpox and related diseases. For registration details, visit SIGA's investor page.
SIGA Technologies, Inc. (SIGA) has received European Medicines Agency (EMA) approval for oral tecovirimat, the same formulation previously approved by the U.S. FDA. The approval allows SIGA to market tecovirimat for treating smallpox, monkeypox, cowpox, and vaccinia complications in the EU, Norway, Iceland, and Liechtenstein. This regulatory milestone supports SIGA's commitment to health security and preparedness against biological threats. The company aims to enhance global access to this critical antiviral medication while maintaining its intellectual property rights.
SIGA Technologies, Inc. (SIGA) announced that Health Canada has approved oral TPOXX® (tecovirimat) for treating human smallpox in adults and children over 13 kg. This approval marks a significant milestone, facilitated by support from the Canadian Department of National Defence, ensuring the continued supply for stockpiling as a key countermeasure. SIGA's TPOXX is a vital antiviral drug that was previously FDA-approved in July 2018. The partnership with Meridian Medical Technologies will promote international sales of TPOXX outside the U.S.
SIGA Technologies, Inc. (SIGA) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) supports the Marketing Authorisation Application for oral tecovirimat, which treats smallpox and related diseases. This recommendation facilitates potential sales across EU member states, Norway, Iceland, and Liechtenstein, with SIGA targeting EMA approval by Q1 2022. SIGA's strategy aims to enhance global access to tecovirimat amid rising infectious disease threats, reflecting its commitment to health security.
SIGA Technologies, Inc. (SIGA) reported financial results for the third quarter of 2021, showing total revenues of $4.8 million, a significant improvement from a net loss of $3.1 million in Q3 2020. For the first nine months, revenues reached $18.3 million, compared to $87.2 million for the same period in 2020. The company is set to deliver approximately $113 million of oral TPOXX® to the U.S. government in Q4 2021. SIGA has repurchased about 1.1 million shares for $7.1 million in Q3 2021, totaling approximately $49 million in its current repurchase program.
SIGA Technologies (NASDAQ: SIGA) announced a conference call on November 4, 2021, at 4:30 P.M. ET, to provide a business update. The call will include CEO Dr. Phil Gomez and CFO Daniel Luckshire, and will be accessible via phone or live webcast. SIGA focuses on health security, primarily through its lead product, TPOXX® (tecovirimat), an antiviral for smallpox treatment, with approximate government orders of $705 million for preparedness. The company emphasizes its role in biodefense and emerging infectious diseases.
SIGA Technologies, Inc. (SIGA) announced the exercise of a procurement option under its BARDA contract, facilitating the delivery of oral TPOXX® treatment courses valued at approximately $112.5 million to the U.S. government. This order is part of a total of approximately $123 million in orders received for 2021, emphasizing the significance of smallpox preparedness. TPOXX® is an antiviral drug for smallpox treatment, with the U.S. government maintaining a stockpile for national health security.
On September 8, 2021, SIGA Technologies CEO, Dr. Phil Gomez, will speak at the NCT USA conference in Baltimore. His presentation focuses on the development of antiviral drugs for epidemic preparedness, emphasizing the critical role of TPOXX® in combating smallpox. Dr. Gomez highlights the importance of robust stockpiling of antiviral drugs to manage future outbreaks effectively. SIGA has procured approximately $705 million of TPOXX for U.S. Government stockpiles, with an additional $300 million in options remaining for future procurement.
SIGA Technologies, Inc. (SIGA) reported second-quarter revenues of $8.7 million, driven by $7 million in international sales of oral TPOXX® to Canada. This marks a continued growth trajectory from $3 million in the previous quarter. However, net income was just $0.2 million with a diluted loss per share of $0.00. The company also announced a new share repurchase program of up to $50 million. The FDA submission for intravenous TPOXX® could expand the market, but the timeline for completion is currently uncertain due to COVID-19 impacts.